Antibody-Drug Conjugate
Jun 05, 2026
The ADC Race in EGFR NSCLC: 5 Contenders Making Big Moves
Summary The EGFR-mutant NSCLC treatment market was valued at USD 6.6 billion in 2025 and is projected to grow at a 7.3% CAGR over the next decade, driven largely by the emergence of targeted biologics and ADCs. The recent approval of Dato-DXd marks a major milestone and is expected to accelerate the adoption...
Read More...
Dec 09, 2025
Kallyope’s Elismetrep Achieves Primary and Secondary Endpoints in Phase 2b Clinical Study; IDEAYA Secures IND Approval to Initiate Clinical Evaluation of IDE034; OMISIRGE Receives FDA Approval; Agios Updates on Regulatory Path for Mitapivat to Treat Thalassemia; Mirum to Acquire Bluejay Therapeutics
Kallyope Reports Successful Phase 2b Trial Outcomes for Elismetrep in Acute Migraine Treatment Kallyope, a late-stage biotechnology company focused on neurological and metabolic therapies, announced positive results from its Phase 2b dose-ranging study of the lead candidate, elismetrep (K-304), for the acute tre...
Read More...
Jul 15, 2025
Nanoscope’s MCO-010 Begins FDA Rolling Submission for Retinitis Pigmentosa; Bayer’s KERENDIA Approved by FDA for Heart Failure With Preserved Ejection Fraction; Klotho Neurosciences’ KLTO-202 Receives FDA Orphan Drug Designation for ALS; Trethera’s TRE-515 Granted FDA Fast Track Designation for Metastatic Prostate Cancer; Adcentrx’s ADRX-0405 Awarded FDA Orphan Drug Designation for Gastric Cancer
Nanoscope Therapeutics Begins FDA Rolling Submission for MCO-010 in Retinitis Pigmentosa Nanoscope Therapeutics has initiated a rolling submission of its Biologics License Application (BLA) to the FDA for MCO-010, a first-in-class, gene-agnostic optogenetic therapy targeting severe vision loss due to retinitis p...
Read More...
Jan 28, 2025
FDA Approves LEQEMBI IV Dosing for Early Alzheimer’s; Vanda Accepts FDA Hearing on Tradipitant for Gastroparesis; Cartesian Gains FDA Protocol Approval for Myasthenia Gravis Trial; Zai Lab Secures FDA Orphan Status for DLL3 ADC in SCLC; Dyne Receives FDA Fast Track for DYNE-101 in Myotonic Dystrophy
FDA Approves LEQEMBI® (Lecanemab-Irmb) IV Maintenance Dosing for Early Alzheimer’s Disease Treatment Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved the Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb), allowing intravenous (IV) maintenance dosing every four week...
Read More...
Jul 02, 2024
Eisai Announces Solo Development of Farletuzumab Ecteribulin (FZEC); Johnson & Johnson’s Nipocalimab Phase III Trial; Merck’s WINREVAIR EU CHMP Recommendation; Verona Pharma’s Ohtuvayre FDA Approval; AstraZeneca’s Lynparza and Imfinzi EU Approval
Eisai Announces Solo Venture for Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate Eisai Co., Ltd. announced the termination of its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), previously known as MORAb-202, an ...
Read More...
Apr 09, 2024
AstraZeneca and Daiichi Sankyo’s Enhertu US Approval; Basilea’s ZEVTERA FDA Approval; Genmab’s ProfoundBio Acquisition; Rocket Pharmaceuticals’ RP-L102 EMA Approval; Alexion’s Ultomiris and Soliris AAN 2024 Data
Enhertu Receives US Approval as First HER2-focused Treatment for Metastatic Solid Tumors, Independent of Tumor Origin AstraZeneca and Daiichi Sankyo's drug Enhertu (trastuzumab deruxtecan) has gained approval in the United States for treating adult patients with inoperable or metastatic HER2-positive (IHC 3+) so...
Read More...
Feb 07, 2024
Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, and Acquisitions in 2024
As we step into the crisp corridors of 2024, the healthcare landscape unfolds a compelling saga of mergers, strategic funding, and transformative acquisitions. In this month-by-month analysis, we delve into the intricate tapestry of industry dynamics, exploring the impactful maneuvers that are shaping the healthcar...
Read More...
Jun 02, 2023
Antibody-drug Conjugates in Oncology: An Overview of the Current and Future Treatment Landscape
Antibody-drug conjugates (ADCs) are becoming more prominent in the cancer treatment market. Antibody-drug conjugates are one of the most rapidly increasing anticancer treatments. This approach uses a mAb attached to a cytotoxic payload via a chemical linker that is directed towards a target antigen expressed on the...
Read More...
Nov 08, 2022
Amgen’s Olpasiran Candidate; GSK’s Novel Antibiotic for Urinary Tract Infections; AstraZeneca and Sanofi’s Beyfortus Approval; FDA Orphan Designation to Anavex’s Anavex2-73; FDA Rare Pediatric Disease Designation to Sensorion’s OTOF-GT; GSK’s Blenrep Fails in Phase III Trial in R/R Multiple Myeloma
Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) - a risk factor for atherosclerotic cardiovascular disease - and now plans to move forward with a phase III program as soon as possi...
Read More...
Apr 11, 2019
Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion
Inozyme Pharma Raises USD 67 Million in Series A2 Financing Inozyme Pharma- a Boston-based biotechnology company, solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The company plans to use this funding to progress its lead asset INZ-701, into clinical trials. INZ-701...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
